XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts

Anti-Cancer Drugs

Volumn 24, Issue 2, 2013, Pages 181-188

  Doudican, Nicole A ^a   Byron, Sara A ^b   Pollock, Pamela M ^b   Orlow, Seth J ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

apoptosis; drug repositioning; mebendazole; melanoma; X linked inhibitor of apoptosis; xenograft

Indexed keywords

MEBENDAZOLE; PROTEASOME; PROTEIN BCL 2; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SMALL INTERFERING RNA; TEMOZOLOMIDE; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; DRUG EXPOSURE; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; DACARBAZINE; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MEBENDAZOLE; MELANOMA; MICE; MICE, NUDE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSPLANTATION, HETEROLOGOUS; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84873099718     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32835a43f1     Document Type: Article

References (43)

1. Roth A, Kirkwood J. Melanoma: Classic approaches to management and current integration of biologic response modifiers. Curr Concepts Oncol 1988; 9:1-11
2. Rigel DS. Cutaneous ultraviolet exposure and its relationship to the development of skin cancer. J Am Acad Dermatol 2008; 58:S129-S132
3. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-2516
4. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18:158-166
5. Ashburn TT, Thor KB. Drug repositioning: Identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004; 3:673-683
6. Duenas-Gonzalez A, Garcia-Lopez P, Herrera LA, Medina-Franco JL, Gonzalez-Fierro A, Candelaria M. The prince and the pauper A tale of anticancer targeted agents. Mol Cancer 2008; 7:82
7. Lacey E. The role of the cytoskeletal protein, tubulin, in the mode of action and mechanism of drug resistance to benzimidazoles. Int J Parasitol 1988; 18:885-936
8. Sajid MS, Iqbal Z, Muhammad G, Iqbal MU. Immunomodulatory effect of various anti-parasitics: A review. Parasitology 2006; 132: 301-313
9. Smego RA Jr, Sebanego P. Treatment options for hepatic cystic echinococcosis. Int J Infect Dis 2005; 9:69-76
10. Teggi A, Capozzi A, De Rosa F. Treatment of Echinococcus granulosus hydatid disease with mebendazole. J Chemother 1989; 1:310-317
11. Davis A, Dixon H, Pawlowski ZS. Multicentre clinical trials of benzimidazolecarbamates in human cystic echinococcosis (phase 2). Bull World Health Organ 1989; 67:503-508
12. Reuter S, Jensen B, Buttenschoen K, Kratzer W, Kern P. Benzimidazoles in the treatment of alveolar echinococcosis: A comparative study and review of the literature. J Antimicrob Chemother 2000; 46:451-456
13. Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-Death proteases. Nature 1997; 388:300-304
14. Chawla-Sarkar M, Bae SI, Reu FJ, Jacobs BS, Lindner DJ, Borden EC. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-Induced apoptosis. Cell Death Differ 2004; 11:915-923
15. Hiscutt EL, Hill DS, Martin S, Kerr R, Harbottle A, Birch-Machin M, et al. Targeting X-linked inhibitor of apoptosis protein to increase the efficacy of endoplasmic reticulum stress-Induced apoptosis for melanoma therapy. J Invest Dermatol 2010; 130:2250-2258
16. Ito T, Deng X, Carr B, May WS. Bcl-2 phosphorylation required for anti-Apoptosis function. J Biol Chem 1997; 272:11671-11673
17. Doudican N, Rodriguez A, Osman I, Orlow SJ. Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells. Mol Cancer Res 2008; 6:1308-1315
18. Brewster JL, Linseman DA, Bouchard RJ, Loucks FA, Precht TA, Esch EA, et al. Endoplasmic reticulum stress and trophic factor withdrawal activate distinct signaling cascades that induce glycogen synthase kinase-3 beta and a caspase-9-Dependent apoptosis in cerebellar granule neurons. Mol Cell Neurosci 2006; 32:242-253
19. Messaritakis J, Psychou P, Nicolaidou P, Karpathios T, Syriopoulou B, Fretzayas A, et al. High mebendazole doses in pulmonary and hepatic hydatid disease. Arch Dis Child 1991; 66:532-533
20. Middleton MR, Kelly J, Thatcher N, Donnelly DJ, McElhinney RS, McMurry TB, et al. O(6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts. Int J Cancer 2000; 85:248-252
21. Middleton MR, Kelly J, Goodger S, Thatcher N, Margison GP. Four-hourly scheduling of temozolomide improves tumour growth delay but not therapeutic index in A375M melanoma xenografts. Cancer Chemother Pharmacol 2000; 45:15-20
22. Tentori L, Leonetti C, Scarsella M, D'Amati G, Vergati M, Portarena I, et al. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res 2003; 9:5370-5379
23. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-Dependent caspase activation by eliminating IAP inhibition. Cell 2000; 102:33-42
24. Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000; 102:43-53
25. Er E, Oliver L, Cartron PF, Juin P, Manon S, Vallette FM. Mitochondria as the target of the pro-Apoptotic protein Bax. Biochim Biophys Acta 2006; 1757:1301-1311
26. De Silva N, Guyatt H, Bundy D. Anthelmintics A comparative review of their clinical pharmacology. Drugs 1997; 53:769-788
27. Mukhopadhyay T, Sasaki J, Ramesh R, Roth JA. Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo. Clin Cancer Res 2002; 8:2963-2969
28. Pourgholami MH, Akhter J, Wang L, Lu Y, Morris DL. Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: In vitro and in a xenograft model of peritoneal carcinomatosis. Cancer Chemother Pharmacol 2005; 55:425-432
29. Martarelli D, Martarelli B, Pompei P. Body composition obtained from the body mass index: An Italian study. Eur J Nutr 2008; 47:409-416
30. Shi J, Orth JD, Mitchison T. Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5. Cancer Res 2008; 68: 3269-3276
31. Bilim V, Yuuki K, Itoi T, Muto A, Kato T, Nagaoka A, et al. Double inhibition of XIAP and Bcl-2 axis is beneficial for retrieving sensitivity of renal cell cancer to apoptosis. Br J Cancer 2008; 98:941-949
32. Alvero AB, O'Malley D, Brown D, Kelly G, Garg M, Chen W, et al. Molecular mechanism of phenoxodiol-Induced apoptosis in ovarian carcinoma cells. Cancer 2006; 106:599-608
33. Galban S, Duckett CS. XIAP as a ubiquitin ligase in cellular signaling. Cell Death Differ 2010; 17:54-60
34. Yang Y, Fang S, Jensen JP, Weissman AM, Ashwell JD. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 2000; 288:874-877
35. Fu J, Jin Y, Arend LJ. Smac3, a novel Smac/DIABLO splicing variant, attenuates the stability and apoptosis-Inhibiting activity of X-linked inhibitor of apoptosis protein. J Biol Chem 2003; 278:52660-52672
36. Nogales E. Structural insight into microtubule function. Annu Rev Biophys Biomol Struct 2001; 30:397-420
37. Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 1996; 56:816-825
38. Yvon AM,Wadsworth P, Jordan MA. Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell 1999; 10:947-959
39. Li Y, McClay EF. Systemic chemotherapy for the treatment of metastatic melanoma. Semin Oncol 2002; 29:413-426
40. Russell GJ, Lacey E. Inhibition of [3H]mebendazole binding to tubulin by structurally diverse microtubule inhibitors which interact at the colchicine binding site. Biochem Mol Biol Int 1995; 35:1153-1159
41. Martarelli D, Pompei P, Baldi C, Mazzoni G. Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice. Cancer Chemother Pharmacol 2008; 61:809-817
42. Sasaki J, Ramesh R, Chada S, Gomyo Y, Roth JA, Mukhopadhyay T. The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells. Mol Cancer Ther 2002; 1:1201-1209
43. Braithwaite PA, Roberts MS, Allan RJ,Watson TR. Clinical pharmacokinetics of high dose mebendazole in patients treated for cystic hydatid disease. Eur J Clin Pharmacol 1982; 22:161-169